# Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

> **NCT04649229** · PHASE4 · COMPLETED · sponsor: **Yale University** · enrollment: 46 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** LCZ 696
- **DRUG:** Placebo
- **DRUG:** Para-aminohippurate
- **DRUG:** Iohexol
- **DRUG:** Aprepitant

## Key facts

- **NCT ID:** NCT04649229
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-27
- **Primary completion:** 2025-05-22
- **Final completion:** 2025-05-22
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04649229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04649229, "Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04649229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*